4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0000950170-24-062645
Chief R&D Officer sold 7,355 shares at $1.75 ($12,871)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-05-17 | Sale : show line 1 in the form | −7,355 | $1.75 | $12,871 | 257,670 | D |
| Open-market sales · 7,355 sh · avg $1.75 · $12,871 | ||||||
Loading xslF345X05/ownership.xml…